

## Vimta Labs Limited

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



VLL\10\S-004\2022\  
Date: 20.01.2022

Listing Centre  
B S E Limited  
P J Towers, Dalal Street  
Mumbai: 400001  
**Scrip Code No.524394**

Asst Vice President  
National Stock Exchange of India Limited  
“Exchange Plaza”, Bandra  
Kurla Complex, Bandra (E)  
Mumbai – 400051  
**Trading Symbol: VIMTALABS**

Dear Sirs,

Sub – Outcome of the Board Meeting.

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) Regulations 2015, please find enclosed herewith Standalone and Consolidated Unaudited Financial Results for the third quarter ended 31<sup>st</sup> December, 2021, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website i.e., <http://www.vimta.com/financials>. Abridged financials are being published in the newspapers (copy enclosed).

The meeting commenced at 11:30 AM and ended at *4:30 PM*

This is for your information and records.

Thanking you,

Yours faithfully,  
for VIMTA LABS LIMITED

  
Sujani Vasireddi  
Company Secretary



Encl: as above.

**Limited Review Report on Standalone Unaudited Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of VIMTA LABS LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company'), for the quarter ended 31 December 2021 and the year to date results for the period 01 April 2021 to 31 December 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.




4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 20-01-2022

for GATTAMANENI & CO.  
Chartered Accountants  
(Firm Regn.No.009303S)



  
G. SRINIVASARAO  
Partner  
ICAI Ms. No.210535

UDIN: 22210535 AAAAJ9683

**Vimta Labs Limited**


Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



Driven by Quality. Inspired by Science.

**Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2021**  
(Amount in INR millions, except Earnings Per Share)


S. No.	Particulars	Quarter Ended			Nine Months ended		Year Ended
		31 Dec 21 (Unaudited)	30 Sep 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Dec 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Mar 21 (Audited)
<b>1</b>	<b>Income from operations</b>						
	(a) Revenue from operations (Refer note no. 6)	666.80	746.96	581.87	2,023.81	1,495.58	2,090.51
	(b) Other income	7.24	1.30	3.04	10.35	5.72	8.10
	<b>Total Income</b>	<b>674.04</b>	<b>748.26</b>	<b>584.91</b>	<b>2,034.16</b>	<b>1,501.30</b>	<b>2,098.61</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed and testing expenditure	166.04	157.00	155.25	494.49	411.35	578.58
	(b) Cost of lab setup (Refer note no. 6)	14.37	104.05	-	118.42	-	-
	(c) Purchase of stock-in-trade	-	-	-	-	-	-
	(d) Changes in inventories of work-in-progress	0.17	1.18	8.56	2.45	29.25	29.84
	(e) Employee benefits expense (Refer note no. 7)	191.23	173.48	158.50	545.17	439.27	602.54
	(f) Finance costs	2.48	2.42	5.81	9.22	14.89	21.67
	(g) Depreciation expense	55.41	54.80	57.31	165.14	171.50	229.37
	(h) Other expenses	91.14	114.97	93.78	296.28	255.40	352.64
	<b>Total Expenses</b>	<b>520.84</b>	<b>607.90</b>	<b>479.21</b>	<b>1,631.17</b>	<b>1,321.66</b>	<b>1,814.64</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items and tax [1-2]</b>	<b>153.20</b>	<b>140.36</b>	<b>105.70</b>	<b>402.99</b>	<b>179.64</b>	<b>283.97</b>
<b>4</b>	<b>Exceptional items</b>	<b>-</b>	<b>12.24</b>	<b>-</b>	<b>12.24</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit/(Loss) before tax [3-4]</b>	<b>153.20</b>	<b>128.12</b>	<b>105.70</b>	<b>390.75</b>	<b>179.64</b>	<b>283.97</b>
<b>6</b>	<b>Tax expense</b>						
	(a) Current tax	40.89	39.92	26.60	114.66	54.20	76.26
	(b) Deferred tax (benefit)/expense	(3.34)	(6.93)	(1.02)	(15.73)	(9.69)	(4.89)
	<b>Total Tax Expense</b>	<b>37.55</b>	<b>32.99</b>	<b>25.58</b>	<b>98.93</b>	<b>44.51</b>	<b>71.37</b>
<b>7</b>	<b>Profit/(Loss) for the period (5-6)</b>	<b>115.65</b>	<b>95.13</b>	<b>80.12</b>	<b>291.82</b>	<b>135.13</b>	<b>212.60</b>
<b>8</b>	<b>Other Comprehensive Income/(expense), net of tax expenses</b>						
	<i>Items that will not be reclassified subsequently to profit or loss :</i>						
	(a) Re-measurements of net defined benefit liability	0.59	0.54	(0.65)	1.68	(1.95)	1.34
	(b) Income tax relating to the items	(0.15)	(0.14)	0.16	(0.42)	0.49	(0.34)
	<b>Total other comprehensive income/(loss), net of tax</b>	<b>0.44</b>	<b>0.40</b>	<b>(0.49)</b>	<b>1.26</b>	<b>(1.46)</b>	<b>1.00</b>
<b>9</b>	<b>Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [7+8])</b>	<b>116.09</b>	<b>95.53</b>	<b>79.63</b>	<b>293.08</b>	<b>133.67</b>	<b>213.60</b>
<b>10</b>	<b>Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)</b>	<b>44.22</b>	<b>44.22</b>	<b>44.22</b>	<b>44.22</b>	<b>44.22</b>	<b>44.22</b>
<b>11</b>	<b>Other Equity</b>						<b>1,898.97</b>
<b>12</b>	<b>Earnings per equity share (EPS) (Face value of Rs.2 per share)</b>						
	(a) Basic (INR)	5.23	4.30	3.62	13.20	6.11	9.62
	(b) Diluted (INR)	5.11	4.21	3.62	12.91	6.11	9.62
	(EPS for the quarter ended are not annualised)						



**Notes to the results :**


- 1 The above unaudited standalone financial results for the quarter and nine months ended December 31, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 20, 2022.
- 2 The results for the quarter and nine months ended December 31, 2021 were subjected to 'limited review' by the statutory auditors of the company. An unmodified report was issued by them thereon.
- 3 These unaudited standalone financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
- 4 The management has identified the reportable segments in accordance with the requirements of Ind AS-108 'Operating Segments', and decided that the Company has only one reportable segment, viz. 'Contract Research and Testing Services'.
- 5 The Company has considered internal and external information upto the date of approval of these standalone financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these standalone financial results.
- 6 During the period of nine months ended with December 31, 2021, the company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. Consequently, the amount of revenues from operations and lab setup expenses for the quarter ended December 31, 2021 and nine months period ended with December 31, 2021 include ₹ 14.37 million and ₹118.42 million respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.
- 7 Pursuant to the shareholders' approval and all necessary regulatory requirements, the Company has constituted the ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)' to grant, offer and Issue options to the employees of the Company. Pursuant to VLESOP-2021, the Nomination and Remuneration Committee has granted 507,769 options to the eligible employees. In respect of stock options granted pursuant to the Company's stock options plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense for the quarter ended December 31, 2021 and nine months ended Decemner 31, 2021 includes employee compensation expense amounting to ₹15.20 million and ₹17.19 million, respectively
- 8 The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of  
Vimta Labs Limited  
CIN: 124110TG1990PLC011977



Harita Vasireddi  
Managing Director

Place : Hyderabad, INDIA  
Date : January 20, 2022




**Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2021**  
(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Nine Months ended		Year ended
		31 Dec 21 (Unaudited)	30 Sep 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Dec 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Mar 21 (Audited)
1	Total Income from Operations	666.80	746.96	581.87	2,023.81	1,495.58	2,090.51
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	153.20	140.36	105.70	402.99	179.64	283.97
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	153.20	128.12	105.70	390.75	179.64	283.97
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	115.65	95.13	80.12	291.82	135.13	212.60
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	116.09	95.53	79.63	293.08	133.67	213.60
6	Equity Share Capital	44.22	44.22	44.22	44.22	44.22	44.22
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						1,898.97
8	Earnings Per Share (of Rs.2/- each) (for continuing and discontinued Operations)						
	1. Basic (INR)	5.23	4.30	3.62	13.20	6.11	9.62
	2. Diluted (INR)	5.11	4.21	3.62	12.91	6.11	9.62


**Note :**

- The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website ([www.vimta.com](http://www.vimta.com)) and on the websites of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)).
- The above unaudited standalone financial results for the quarter and nine months ended December 31, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 20, 2022.
- Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of  
**Vimta Labs Limited**  
CIN: L24110TG1990PLC011977

  
**Harita Vasireddi**  
Managing Director

Place : Hyderabad, INDIA  
Date : January 20, 2022







**Limited Review Report on Consolidated Unaudited Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of VIMTA LABS LIMITED**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Holding Company') and M/s.EMTAC Laboratories Private Limited, wholly owned subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended 31 December 2021 and the year to date results for the period 01 April 2021 to 31 December 2021, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.




We also performed procedures in accordance with Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 20-01-2022

for GATTAMANENI & CO.  
Chartered Accountants  
(Firm Regn.No.009303S)



  
G. SRINIVASARAO  
Partner  
ICAI Ms. No.210535

UDIN: 222 10535 AAAAK 3242




**Vimta Labs Limited**

Registered Office  
142, IDA Phase II, Cherlapally  
Hyderabad-500 051, Telangana, India  
T : +91 40 2726 4141  
F : +91 40 2726 3657



**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2021**  
(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31 Dec 21 (Unaudited)	30 Sep 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Dec 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Mar 21 (Audited)
1	<b>Income from operations</b>						
	(a) Revenue from operations (Refer note no. 6)	673.40	754.97	586.76	2,041.91	1,508.37	2,106.79
	(b) Other income	7.14	1.21	3.24	10.10	5.94	8.29
	<b>Total Income</b>	<b>680.54</b>	<b>756.18</b>	<b>590.00</b>	<b>2,052.01</b>	<b>1,514.31</b>	<b>2,115.08</b>
2	<b>Expenses</b>						
	(a) Cost of materials consumed and testing expenditure	167.43	158.56	156.15	497.97	413.67	581.30
	(b) Cost of lab setup (Refer note no. 6)	14.37	104.05	-	118.42	-	-
	(c) Purchase of stock-in-trade	-	-	-	-	-	-
	(d) Changes in inventories of work-in-progress	0.17	1.18	8.56	2.45	29.25	29.84
	(e) Employee benefits expense (Refer note no. 7)	192.62	174.81	159.92	549.15	443.03	607.78
	(f) Finance costs	2.48	2.43	5.81	9.23	14.89	21.68
	(g) Depreciation expense	55.84	55.22	57.67	166.44	172.54	230.78
	(h) Other expenses	92.86	116.89	95.58	301.52	259.74	358.30
	<b>Total Expenses</b>	<b>525.77</b>	<b>613.14</b>	<b>483.69</b>	<b>1,645.18</b>	<b>1,333.12</b>	<b>1,829.68</b>
3	Profit/(Loss) before exceptional items and tax [1-2]	154.77	143.04	106.31	406.83	181.19	285.40
4	Exceptional items	-	12.24	-	12.24	-	-
5	Profit/(Loss) before tax [3-4]	154.77	130.80	106.31	394.59	181.19	285.40
6	<b>Tax expense</b>						
	(a) Current tax	41.35	40.34	26.60	115.53	54.20	76.26
	(b) Deferred tax (benefit)/expense	(3.40)	(6.98)	(0.98)	(15.90)	(9.64)	(4.91)
	<b>Total Tax Expense</b>	<b>37.95</b>	<b>33.36</b>	<b>25.62</b>	<b>99.63</b>	<b>44.56</b>	<b>71.35</b>
7	Profit/(Loss) for the period (5-6)	116.82	97.44	80.69	294.96	136.63	214.05
8	<b>Other Comprehensive Income/(expense), net of tax expenses</b>						
	<i>Items that will not be reclassified subsequently to profit or loss :</i>						
	(a) Re-measurements of net defined benefit liability	0.59	0.54	(0.65)	1.68	(1.95)	1.34
	(b) Income tax relating to the items	(0.15)	(0.14)	0.17	(0.42)	0.49	(0.34)
	<b>Total other comprehensive income/(loss), net of tax</b>	<b>0.44</b>	<b>0.40</b>	<b>(0.48)</b>	<b>1.26</b>	<b>(1.46)</b>	<b>1.00</b>
9	<b>Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [7+8])</b>	<b>117.26</b>	<b>97.84</b>	<b>80.21</b>	<b>296.22</b>	<b>135.17</b>	<b>215.05</b>
10	Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)	44.22	44.22	44.22	44.22	44.22	44.22
11	Other Equity						1,899.60
12	<b>Earnings per equity share (EPS) (Face value of Rs.2 per share)</b>						
	(a) Basic (INR)	5.28	4.41	3.65	13.34	6.18	9.68
	(b) Diluted (INR)	5.17	4.31	3.65	13.04	6.18	9.68
	(EPS for the quarter ended are not annualised)						



**Notes to the results :**

- 1 The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 20, 2022.
- 2 The results for the quarter and nine months ended December 31, 2021 were subjected to 'limited review' by the statutory auditors of the company. An unmodified report was issued by them thereon.
- 3 These unaudited consolidated financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
- 4 The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'.
- 5 The Group has considered internal and external information up to the date of approval of these consolidated financial results in assessing the recoverability of financial and non financial assets, based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these consolidated financial results.
- 6 During the period of nine months ended with December 31, 2021, the holding company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. Consequently, the amount of revenues from operations and lab setup expenses for the quarter ended December 31, 2021 and nine months period ended with December 31, 2021 include ₹14.37 million and ₹118.42 million respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.
- 7 Pursuant to the shareholders' approval and all necessary regulatory requirements, the Company has constituted the ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)' to grant, offer and issue options to the employees of the Company. Pursuant to VLESOP-2021, the Nomination and Remuneration Committee has granted 507,769 options to the eligible employees. In respect of stock options granted pursuant to the Company's stock options plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense for the quarter ended December 31, 2021 and nine months ended December 31, 2021 includes employee compensation expense amounting to ₹15.20 million and ₹17.19 million, respectively
- 8 The previous periods figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of  
Vimta Labs Limited  
CIN: L24110TG1990PLC011977



Harita Vasireddi  
Managing Director

Place : Hyderabad, INDIA  
Date : January 20, 2022




Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2021  
(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31 Dec 21 (Unaudited)	30 Sep 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Dec 21 (Unaudited)	31 Dec 20 (Unaudited)	31 Mar 21 (Audited)
1	Total Income from Operations	673.40	754.97	586.76	2,041.91	1,508.37	2,106.79
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	154.77	143.04	106.31	406.83	181.19	285.40
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary Items)	154.77	130.80	106.31	394.59	181.19	285.40
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary Items)	116.82	97.44	80.69	294.96	136.63	214.05
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	117.26	97.84	80.21	296.22	135.17	215.05
6	Equity Share Capital	44.22	44.22	44.22	44.22	44.22	44.22
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						1,899.60
8	Earnings Per Share (of Rs.2/- each) (for continuing and discontinued Operations)						
	1. Basic (INR)	5.28	4.41	3.65	13.34	6.18	9.68
	2. Diluted (INR)	5.17	4.31	3.65	13.04	6.18	9.68


Note :

- The above is an extract of the detailed format of Quarterly and Nine months ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's Website ([www.vimta.com](http://www.vimta.com)) and on the websites of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and the National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)).
- The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2021 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 20, 2022.
- Figures of the previous periods have been regrouped/recast/reclassified wherever considered necessary.

For and on behalf of the Board of Directors of  
Vimta Labs Limited  
CIN: L24110TG1990PLC011977

  
Harita Vasireddi  
Managing Director

Place : Hyderabad, INDIA  
Date : January 20, 2022



*(Handwritten initials)*

*(Handwritten initials)*